1.88
price up icon5.03%   0.09
after-market アフターアワーズ: 1.85 -0.03 -1.60%
loading
前日終値:
$1.79
開ける:
$1.77
24時間の取引高:
1.90M
Relative Volume:
1.38
時価総額:
$42.64M
収益:
$151.12M
当期純損益:
$-194.97M
株価収益率:
-0.1246
EPS:
-15.0871
ネットキャッシュフロー:
$-59.11M
1週間 パフォーマンス:
+16.77%
1か月 パフォーマンス:
-2.59%
6か月 パフォーマンス:
-77.62%
1年 パフォーマンス:
-67.19%
1日の値動き範囲:
Value
$1.6701
$1.885
1週間の範囲:
Value
$1.525
$1.885
52週間の値動き範囲:
Value
$1.24
$10.99

Karyopharm Therapeutics Inc Stock (KPTI) Company Profile

Name
名前
Karyopharm Therapeutics Inc
Name
セクター
Healthcare (1065)
Name
電話
617-658-0600
Name
住所
85 WELLS AVENUE, NEWTON, MA
Name
職員
228
Name
Twitter
@Karyopharm
Name
次回の収益日
2026-11-02
Name
最新のSEC提出書
Name
KPTI's Discussions on Twitter

Compare KPTI vs VRTX, REGN, ARGX, MRNA, RVMD

株式 価格 時価総額 収益 当期純利益 現金流量 EPS
KPTI icon
KPTI
Karyopharm Therapeutics Inc
1.88 36.52M 151.12M -194.97M -59.11M -15.09
VRTX icon
VRTX
Vertex Pharmaceuticals Inc
508.34 130.64B 12.34B 4.34B 3.71B 16.87
REGN icon
REGN
Regeneron Pharmaceuticals Inc
784.85 80.46B 14.92B 4.42B 3.79B 41.04
ARGX icon
ARGX
Argen X Se Adr
990.32 61.58B 4.16B 1.29B 734.26M 19.58
MRNA icon
MRNA
Moderna Inc
154.04 57.48B 2.23B -3.19B -1.60B -8.1462
RVMD icon
RVMD
Revolution Medicines Inc
190.95 43.68B 742.00K -1.37B -1.07B -7.0731

Karyopharm Therapeutics Inc Stock (KPTI) Upgrades & Downgrades

日付 アクション アナリスト 評価の変更
2026-03-10 開始されました Rodman & Renshaw Buy
2026-02-05 開始されました Cantor Fitzgerald Overweight
2025-10-13 アップグレード H.C. Wainwright Neutral → Buy
2025-07-16 ダウングレード H.C. Wainwright Buy → Neutral
2025-07-11 再開されました H.C. Wainwright Buy
2023-01-19 開始されました Piper Sandler Overweight
2022-11-04 アップグレード RBC Capital Mkts Sector Perform → Outperform
2022-02-09 アップグレード JP Morgan Underweight → Neutral
2021-11-19 再開されました Morgan Stanley Equal-Weight
2021-08-06 ダウングレード JP Morgan Overweight → Neutral
2021-08-06 ダウングレード RBC Capital Mkts Outperform → Sector Perform
2021-08-06 ダウングレード SVB Leerink Outperform → Mkt Perform
2020-07-02 開始されました Morgan Stanley Overweight
2020-03-04 開始されました Barclays Overweight
2020-01-17 ダウングレード Wedbush Outperform → Neutral
2019-07-23 アップグレード JP Morgan Neutral → Overweight
2019-07-05 繰り返されました H.C. Wainwright Buy
2019-07-05 繰り返されました Robert W. Baird Outperform
2019-03-01 ダウングレード JP Morgan Overweight → Neutral
2019-02-28 繰り返されました BofA/Merrill Underperform
2019-02-27 ダウングレード BofA/Merrill Neutral → Underperform
2019-01-03 アップグレード BofA/Merrill Underperform → Neutral
2018-12-03 開始されました B. Riley FBR Buy
2018-11-09 アップグレード Wedbush Neutral → Outperform
2018-05-24 ダウングレード Wedbush Outperform → Neutral
2018-04-02 再開されました Leerink Partners Outperform
2017-11-15 再開されました H.C. Wainwright Buy
2017-09-15 開始されました RBC Capital Mkts Outperform
2016-09-08 繰り返されました H.C. Wainwright Buy
2016-08-30 アップグレード Jefferies Hold → Buy
2016-08-18 開始されました H.C. Wainwright Buy
2016-06-28 開始されました Robert W. Baird Outperform
すべてを表示

Karyopharm Therapeutics Inc (KPTI) 最新ニュース

pulisher
Sep 11, 2026

KPTI Slides As Legal, Cash Pressures Rattle Traders - StocksToTrade

Sep 11, 2026
pulisher
Sep 11, 2026

Form 8K Karyopharm Therapeutics Inc For: 11 September By Investing.com - Investing.com South Africa

Sep 11, 2026
pulisher
Sep 11, 2026

Karyopharm Skips $15.8 Million Debt Payment, Warns of Going-Concern Risk - Minichart

Sep 11, 2026
pulisher
Sep 11, 2026

KPTI Looks 64.4% Undervalued on GF Value™ but Faces Significant Financial Struggles - GuruFocus

Sep 11, 2026
pulisher
Sep 11, 2026

Karyopharm TherapeuticsEnters Forbearance Agreement And Waiver On Sept 10, 2026SEC Filing - TradingView

Sep 11, 2026
pulisher
Sep 11, 2026

Karyopharm Wins Forbearance to Oct. 15, Will Issue $20M 0% Convertible Preferred - TradingView

Sep 11, 2026
pulisher
Sep 11, 2026

Karyopharm pushes off debt payment; Amgen eyes broader Imdelltra use - Yahoo Finance

Sep 11, 2026
pulisher
Sep 11, 2026

SpaceX Stock Price Today | SPCX Ticker, News, Retail Sentiment - Stocktwits

Sep 11, 2026
pulisher
Sep 09, 2026

Karyopharm Therapeutics Inc (NASDAQ: KPTI) Share Price, KPTI Stock News, KPTI Share Price & Updates - Kalkine

Sep 09, 2026
pulisher
Sep 06, 2026

Why Is KPTI Stock Down 69% After-Hours Today? - Stocktwits

Sep 06, 2026
pulisher
Sep 05, 2026

Karyopharm Therapeutics Stock Price Forecast. Should You Buy KPTI? - StockInvest.us

Sep 05, 2026
pulisher
Sep 04, 2026

Israel Englander group discloses new Karyopharm stake (NASDAQ: KPTI) - Stock Titan

Sep 04, 2026
pulisher
Sep 04, 2026

Karyopharm Therapeutics (KPTI) Stock Fair Value Falls After Split Analyst Views On Trial Updates - Yahoo Finance

Sep 04, 2026
pulisher
Sep 01, 2026

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4) - TradingView

Sep 01, 2026
pulisher
Sep 01, 2026

Karyopharm Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Karyopharm

Sep 01, 2026
pulisher
Sep 01, 2026

Karyopharm Seeks FDA Approval for XPOVIO Plus Ruxolitinib in Myelofibrosis - Cure Today

Sep 01, 2026
pulisher
Sep 01, 2026

A Second Drug for a Disease That Has Only Ever Had One: Karyopharm Files for Selinexor Plus Ruxolitinib in Myelofibrosis - Onco'Zine

Sep 01, 2026
pulisher
Aug 31, 2026

Karyopharm Therapeutics Submits Supplemental New Drug Application to the Fda for Xpovio Plus Ruxolitinib for Patients with Myelofibrosis - marketscreener.com

Aug 31, 2026
pulisher
Aug 31, 2026

Karyopharm Therapeutics submits sNDA seeking accelerated approval for selinexor plus ruxolitinib in myelofibrosis - TradingView

Aug 31, 2026
pulisher
Aug 31, 2026

KPTI Looks 60.5% Undervalued on GF Value™ Amid Challenging Funda - GuruFocus

Aug 31, 2026
pulisher
Aug 31, 2026

Karyopharm Submits Supplemental New Drug Application to the FDA for XPOVIO® (selinexor) Plus Ruxolitinib for Patients with Myelofibrosis - Karyopharm

Aug 31, 2026
pulisher
Aug 25, 2026

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Karyopharm Therapeutics Inc.KPTI - FinancialContent

Aug 25, 2026
pulisher
Aug 21, 2026

Karyopharm’s (KPTI) Big Cancer Bet Faces A Ticking Clock - Yahoo Finance

Aug 21, 2026
pulisher
Aug 20, 2026

Conferencia de resultados del 2T de 2026 de Karyopharm (KPTI): foco en la sNDA de selinexor y la liquidez - TradingKey

Aug 20, 2026
pulisher
Aug 20, 2026

Karyopharm (KPTI) Q2 2026 Earnings Call Transcript - AOL.com

Aug 20, 2026
pulisher
Aug 19, 2026

KPTI Stock Price and Chart — NASDAQ:KPTI - TradingView

Aug 19, 2026
pulisher
Aug 16, 2026

Earnings Release: Here's Why Analysts Cut Their Karyopharm Therapeutics Inc. (NASDAQ:KPTI) Price Target To US$6.40 - simplywall.st

Aug 16, 2026
pulisher
Aug 14, 2026

RA Capital boosts Karyopharm (KPTI) stake to 9.99% beneficial ownership cap - Stock Titan

Aug 14, 2026
pulisher
Aug 14, 2026

Karyopharm Therapeutics (KPTI): Commodore Capital now reports 0.0% ownership - Stock Titan

Aug 14, 2026
pulisher
Aug 14, 2026

KPTI|Karyopharm Therapeutics Inc|Price:2.015|Chg%:+0.025 - TradingKey

Aug 14, 2026
pulisher
Aug 14, 2026

Karyopharm Therapeutics Inc. Q2 2026 Earnings Call Summary - Yahoo Finance

Aug 14, 2026
pulisher
Aug 14, 2026

Karyopharm (KPTI) Ergebniskonferenz Q2 2026: Fokus auf Selinexor-sNDA und Liquidität - TradingKey

Aug 14, 2026
pulisher
Aug 13, 2026

Karyopharm Therapeutics Inc (KPTI) Earnings, Actual EPS, EPS Estimates & Results - Stocktwits

Aug 13, 2026
pulisher
Aug 13, 2026

Karyopharm Therapeutics Inc (KPTI) (Q2 2026) Earnings Call Highlights: SENTRY Trial Success and ... - Yahoo! Finance Canada

Aug 13, 2026
pulisher
Aug 13, 2026

Karyopharm Therapeutics Inc (KPTI) (Q2 2026) Earnings Call Highl - GuruFocus

Aug 13, 2026
pulisher
Aug 13, 2026

It's crunch time for Karyopharm as company faces potential default next month - Fierce Pharma

Aug 13, 2026
pulisher
Aug 13, 2026

Karyopharm Therapeutics has cash to last only into next month - The Business Journals

Aug 13, 2026
pulisher
Aug 13, 2026

Karyopharm Therapeutics Releases Q2 2026 Financial Results - AlphaStreet

Aug 13, 2026
pulisher
Aug 13, 2026

Karyopharm Q2 2026 slides: myelofibrosis sNDA planned for August By Investing.com - Investing.com Australia

Aug 13, 2026
pulisher
Aug 13, 2026

Karyopharm Therapeutics Q2 2026 Earnings Call Transcript - marketbeat.com

Aug 13, 2026
pulisher
Aug 13, 2026

Karyopharm Q2 2026 slides: myelofibrosis sNDA planned for August - Investing.com

Aug 13, 2026
pulisher
Aug 13, 2026

Karyopharm Q2 2026 slides: myelofibrosis data shines amid cash crunch - Investing.com

Aug 13, 2026
pulisher
Aug 13, 2026

Karyopharm Therapeutics Inc. reports results for the quarter ended June 30Earnings Summary - TradingView

Aug 13, 2026
pulisher
Aug 13, 2026

KPTI: Selinexor sNDA for myelofibrosis advances amid strong data, stable sales, and liquidity focus - TradingView

Aug 13, 2026
pulisher
Aug 13, 2026

Earnings call transcript: Karyopharm Q2 2026 loss widens as cash pressure mounts - Investing.com

Aug 13, 2026
pulisher
Aug 13, 2026

Karyopharm Therapeutics Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:KPTI) 2026-08-13 - Seeking Alpha

Aug 13, 2026
pulisher
Aug 13, 2026

Form 8K Karyopharm Therapeutics Inc For: 13 August By Investing.com - Investing.com Nigeria

Aug 13, 2026
pulisher
Aug 13, 2026

Karyopharm Therapeutics Reports Q2 2026 Results: Full Earnings Call Transcript - Benzinga

Aug 13, 2026
pulisher
Aug 13, 2026

Karyopharm Therapeutics (KPTI) Reports Q2 Loss, Beats Revenue Estimates - Yahoo Finance

Aug 13, 2026
pulisher
Aug 13, 2026

Karyopharm Therapeutics Inc. Reaffirms Earnings Guidance for the Full-Year of 2026 - marketscreener.com

Aug 13, 2026
pulisher
Aug 13, 2026

Is Karyopharm Therapeutics Inc (KPTI) Undervalued at 64.1%? Q2 E - GuruFocus

Aug 13, 2026

Karyopharm Therapeutics Inc (KPTI) 財務データ

収益

loading

当期純利益

loading

現金流量

loading

EPS

loading

Karyopharm Therapeutics Inc (KPTI) インサイダートレーディング

インサイダートレーディング 関係 日付 取引 コスト #株式 値 ($) #株式総数
Poulton Stuart
EVP, Chief Development Officer
Jul 28 '26
Sale
7.10
189
1,342
94,632
Poulton Stuart
EVP, Chief Development Officer
May 14 '26
Sale
9.50
403
3,828
94,821
Rangwala Reshma
EVP & Chief Medical Officer
May 14 '26
Sale
9.50
408
3,876
56,829
Cheng Sohanya Roshan
EVP & Chief Commercial Officer
May 14 '26
Sale
9.50
324
3,078
107,940
Abate Kristin
Chief Accounting Officer
May 14 '26
Sale
9.50
53
504
23,801
Paulson Richard A.
President and CEO
May 14 '26
Sale
9.50
2,203
20,928
269,747
Mano Michael
EVP, CLO&Secretary
May 14 '26
Sale
9.50
266
2,527
94,398
Rangwala Reshma
EVP & Chief Medical Officer
Apr 21 '26
Sale
8.94
449
4,014
56,290
Mano Michael
EVP, CLO&Secretary
Mar 02 '26
Sale
9.41
3,526
33,178
93,964
Rangwala Reshma
EVP & Chief Medical Officer
Mar 02 '26
Sale
9.41
5,066
47,669
56,739
$58.41
price down icon 0.88%
$120.00
price down icon 3.21%
$39.77
price down icon 0.53%
$239.56
price down icon 2.42%
ONC ONC
$350.84
price down icon 0.74%
$190.95
price down icon 3.04%
大文字化:     |  ボリューム (24 時間):